These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 28667026

  • 1. HtrA1 Down-regulation Induces Cisplatin Resistance in Colon Cancer by Increasing XIAP and Activating PI3K/Akt Pathway.
    Xiong Z, Fu Z, Shi J, Jiang X, Wan H.
    Ann Clin Lab Sci; 2017 May; 47(3):264-270. PubMed ID: 28667026
    [Abstract] [Full Text] [Related]

  • 2. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y, Jiang Z, Zhang Z, Sun N, Zhang M, Xie J, Li T, Hou Y, Wu D.
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [Abstract] [Full Text] [Related]

  • 3. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
    Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK.
    Cancer Res; 2003 Nov 01; 63(21):7081-8. PubMed ID: 14612499
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation.
    He X, Khurana A, Maguire JL, Chien J, Shridhar V.
    Int J Cancer; 2012 Mar 01; 130(5):1029-35. PubMed ID: 21387310
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
    Fu X, Feng J, Zeng D, Ding Y, Yu C, Yang B.
    Biosci Rep; 2014 Apr 01; 34(2):. PubMed ID: 27919028
    [Abstract] [Full Text] [Related]

  • 8. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
    Wang LJ, Wang SG, Deng TX.
    Sheng Li Xue Bao; 2018 Aug 25; 70(4):397-405. PubMed ID: 30112565
    [Abstract] [Full Text] [Related]

  • 9. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
    Ali AY, Kim JY, Pelletier JF, Vanderhyden BC, Bachvarov DR, Tsang BK.
    Mol Carcinog; 2015 Nov 25; 54(11):1301-14. PubMed ID: 25154814
    [Abstract] [Full Text] [Related]

  • 10. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
    Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, Sun B, Zhang Q, Wang X, Jiang H, Krissansen GW, Qiao H, Sun X.
    FEBS J; 2014 Jan 25; 281(1):115-28. PubMed ID: 24165223
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
    Su J, Zhang F, Li X, Liu Z.
    Biochem Biophys Res Commun; 2019 Jun 25; 514(2):510-517. PubMed ID: 31056260
    [Abstract] [Full Text] [Related]

  • 13. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S, Choi EJ, Jin C, Kim DH.
    Gynecol Oncol; 2005 Apr 25; 97(1):26-34. PubMed ID: 15790433
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MTA1 overexpression induces cisplatin resistance in nasopharyngeal carcinoma by promoting cancer stem cells properties.
    Feng X, Zhang Q, Xia S, Xia B, Zhang Y, Deng X, Su W, Huang J.
    Mol Cells; 2014 Sep 25; 37(9):699-704. PubMed ID: 25245523
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
    Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX.
    Oncol Res; 2003 Sep 25; 13(6-10):399-404. PubMed ID: 12725530
    [Abstract] [Full Text] [Related]

  • 19. Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
    Tang C, Luo H, Luo D, Yang H, Zhou X.
    Oncol Rep; 2018 Feb 25; 39(2):611-618. PubMed ID: 29207183
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X, Huang L, Zhao Y, Tan W.
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec 25; 45(12):995-1001. PubMed ID: 24145606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.